SCYNEXIS (FRA:135) Cyclically Adjusted Book per Share: €38.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:135 SCYNEXIS Inc FRA:135
40 GF Score
Price €4.36
GF Value €14.60
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Cyclically Adjusted Book per Share?

SCYNEXIS FRA:135 +1.40% 40 Cyclically Adjusted Book per Share is €38.51 as of Jun. 2026. GuruFocus rates FRA:135 with a GF Score™ of 40/100 and a GF Value™ of €14.60. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

SCYNEXIS's adjusted book value per share for the three months ended in Jun. 2026 was €5.839. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €38.51 for the trailing ten years ended in Jun. 2026.

During the past 12 months, SCYNEXIS's average Cyclically Adjusted Book Growth Rate was -44.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of SCYNEXIS was 1.30% per year. The lowest was 1.30% per year. And the median was 1.30% per year.

As of today (2026-08-16), SCYNEXIS's current stock price is €4.355. SCYNEXIS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €38.51. SCYNEXIS's Cyclically Adjusted PB Ratio of today is 0.11.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of SCYNEXIS was 0.99. The lowest was 0.08. And the median was 0.15.


SCYNEXIS  (FRA:135) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

SCYNEXIS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=4.355/38.51
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of SCYNEXIS was 0.99. The lowest was 0.08. And the median was 0.15.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


SCYNEXIS Cyclically Adjusted Book per Share Related Terms


SCYNEXIS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Cyclically Adjusted Book per Share Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 37.75 69.68 61.79 37.04

SCYNEXIS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.83 46.24 37.04 33.47 38.51

FRA:135 vs IXHL, ETST, INIS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted PB Ratio falls into.


FRA:135
40GF Score
SCYNEXIS Inc FRA:135
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SCYNEXIS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.839/333.9520*333.9520
=5.839

Current CPI (Jun. 2026) = 333.9520.

SCYNEXIS Quarterly Data

Book Value per Share CPI Adj_Book
201609 100.887 241.428 139.551
201612 107.169 241.432 148.238
201703 98.285 243.801 134.628
201706 85.118 244.955 116.043
201709 64.616 246.819 87.427
201712 49.975 246.524 67.698
201803 50.990 249.554 68.235
201806 38.787 251.989 51.403
201809 40.495 252.439 53.571
201812 45.745 251.233 60.807
201903 15.967 254.202 20.976
201906 13.499 256.143 17.600
201909 7.780 256.759 10.119
201912 9.529 256.974 12.383
202003 4.777 258.115 6.181
202006 4.293 257.797 5.561
202009 6.011 260.280 7.712
202012 7.611 260.474 9.758
202103 8.447 264.877 10.650
202106 9.273 271.696 11.398
202109 10.707 274.310 13.035
202112 10.176 278.802 12.189
202203 9.676 287.504 11.239
202206 10.558 296.311 11.899
202209 4.258 296.808 4.791
202212 0.747 296.797 0.841
202303 -6.707 301.836 -7.421
202306 18.487 305.109 20.235
202309 18.549 307.789 20.126
202312 14.385 306.746 15.661
202403 14.438 312.332 15.437
202406 11.859 314.175 12.606
202409 11.118 315.301 11.776
202412 11.080 315.605 11.724
202503 9.582 319.799 10.006
202506 7.873 322.561 8.151
202509 5.918 324.800 6.085
202512 7.747 324.054 7.984
202603 4.607 330.213 4.659
202606 5.839 333.952 5.839

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €38.51 mean?
SCYNEXIS (FRA:135) has a Cyclically Adjusted Book per Share of €38.51 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's Cyclically Adjusted Book per Share too high?
SCYNEXIS's current Cyclically Adjusted Book per Share is €38.51. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Cyclically Adjusted Book per Share compare to IXHL and ETST?
SCYNEXIS's Cyclically Adjusted Book per Share of €38.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Cyclically Adjusted Book per Share is €38.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (FRA:135) has a current Cyclically Adjusted Book per Share of €38.51. The stock's GF Value™ is €14.60, compared to a current price of €4.36 — trading 70.2% below its estimated fair value. The current Cyclically Adjusted Book per Share is €38.51. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For SCYNEXIS (FRA:135), the current Cyclically Adjusted Book per Share is €38.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (FRA:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.36 is trading 70.2% below its estimated GF Value™ of €14.60.

Key valuation signals for FRA:135:

  • Cyclically Adjusted Book per Share: €38.51
  • GF Value™: €14.60 vs. price of €4.36 (70.2% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the FRA:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score

Get the complete analysis for FRA:135

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.36
Price
€14.60
GF Value